Sort   by:  
 Page size 
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownBaseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).
Not available
S-EPMC4011688 | biostudies-literature
UnknownVasopressor use after noncardiac surgery: an international observational study.
Not available
S-EPMC12799376 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327 | biostudies-literature
UnknownRemdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
Not available
S-EPMC9060606 | biostudies-literature
UnknownImplementation of Recommendations on the Use of Corticosteroids in Severe COVID-19.
Not available
S-EPMC10751594 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownAssociation of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19.
Not available
S-EPMC10219675 | biostudies-literature
UnknownThrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry.
Not available
S-EPMC10439444 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
Sort   by:  
 Page size